Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415502 | 1.00 | IDO1 (0.58) | IDO1HTR2ARETTSHRADRA2A | |
| SCHEMBL40422 | 1.00 | IDO1 (0.58) | IDO1HTR2ARETTSHRADRA2A | |
| SCHEMBL30837489 | 1.00 | IDO1 (0.58) | IDO1HTR2ARETTSHRADRA2A | |
| SCHEMBL14543304 | 1.00 | IDO1 (0.58) | IDO1HTR2ARETTSHRADRA2A | |
| SCHEMBL10774751 | 1.00 | IDO1 (0.58) | IDO1HTR2ARETTSHRADRA2A | |
| SCHEMBL469047 | 1.00 | IDO1 (0.58) | IDO1HTR2ARETTSHRADRA2A | |
| Bromide SCHEMBL3727459 | 0.98 | IDO1 (0.56) | IDO1HTR2ARETADRA2AADRA1A | |
| Methane SCHEMBL9503230 | 0.98 | IDO1 (0.56) | IDO1HTR2ARETADRA2AADRA1A | |
| Hydrochloric Acid SCHEMBL7424398 | 0.98 | IDO1 (0.59) | IDO1HTR2ARET | |
| Hydrochloric Acid SCHEMBL29757860 | 0.98 | IDO1 (0.59) | IDO1HTR2ARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 838 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250078176-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2025-03-06 | — | — | US | claimed |
| US-12104106-B2 | Compositions of chiral molecules and perovskite nanocrystals and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2024-10-01 | — | — | US | claimed |
| CN-113668261-B | Dyeing liquid for optical resin and application method thereof | 拓烯科技(衢州)有限公司 | 2023-07-07 | — | — | CN | claimed |
| WO-2023117926-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2023-06-29 | — | — | WO | claimed |
| US-20220326082-A1 | CHIRAL HETEROSTRUCTURES | Alliance for Energy Innovation, LLC | 2022-10-13 | — | — | US | claimed |
| CN-110003084-B | Organic circular polarization luminescent material with both mechanoluminescence and aggregation-induced luminescence characteristics, and preparation method and application thereof | 华南师范大学 | 2022-08-02 | — | — | CN | claimed |
| CN-113121410-B | Organic circular polarization luminescent material and preparation method and application thereof | 华南师范大学 | 2022-05-20 | — | — | CN | claimed |
| CN-113668261-A | Dyeing liquid for optical resin and application method thereof | 拓烯科技(衢州)有限公司 | 2021-11-19 | — | — | CN | claimed |
| CN-113121410-A | Organic circular polarization luminescent material and preparation method and application thereof | 华南师范大学 | 2021-07-16 | — | — | CN | claimed |
| US-10919913-B2 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-16 | — | — | US | claimed |
| US-D646886-S1 | Tip of an umbrella | Pro Performance Sports, L.L.C. (US) | 2011-10-18 | — | — | US | claimed |
| WO-2010081053-A2 | TRANSAMINASE POLYPEPTIDES | CODEXIS, INC. (US) | 2010-07-15 | — | — | WO | claimed |
| US-20100174077-A1 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-08 | — | — | US | claimed |
| EP-1934179-B1 | PROCESSES AND INTERMEDIATES | VERTEX PHARMA (US) | 2010-04-07 | — | — | EP | claimed |
| US-20100063252-A1 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED | 2010-03-11 | — | — | US | claimed |
| EP-2098519-A1 | Process for the synthesis of ramelteon and its intermediates | Teva Pharmaceutical Industries Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | claimed |
| EP-1934179-A2 | PROCESSES AND INTERMEDIATES | Vertex Pharmaceuticals Incorporated (US) | 2008-06-25 | — | — | EP | claimed |
| US-20070087973-A1 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-19 | — | — | US | claimed |
| WO-2007022459-A2 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063252-A1 | PROCESSES AND INTERMEDIATES | TFPI, SPINT2, SERPINB1 | IDO1 1892/4885HTR2A 4247/4885RET 4171/4885 |
| US-20070087973-A1 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | PRSS1, CTRL, TMPRSS2 | IDO1 348/4885HTR2A 1137/4885RET 3860/4885 |
| US-20100174077-A1 | Processes and intermediates | TFPI, SPINT2, SERPINB1 | IDO1 1892/4885HTR2A 4247/4885RET 4171/4885 |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | IDO1 2791/4885HTR2A 2028/4885RET 2809/4885 |
| US-10919913-B2 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors | TP53, MDM2, FOXM1 | IDO1 13/4885HTR2A 486/4885RET 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.